Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.

Trial Details

NCT ID
NCT07006727
Phase
PHASE1
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • 225Ac-ETN029
  • 111In-ETN029
Locations (sample)
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Royal Oak, Michigan, United States|42.48948,-83.14465
  • Seattle, Washington, United States|47.60621,-122.33207
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Age ≥ 18 years old
  • Patients with one of the following indications:
  • Locally advanced, unresectable, or metastatic SCLC with disease progression following, or intolerance to, at least 1 line of systemic therapy, incl…
  • Dose escalation only: LCNEC of the lung with disease progression following, or intolerance to, at least 1 line of systemic therapy, including plati…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →